

OUR MISSION

The Society for Immunotherapy of Cancer (SITC) is the world's leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. SITC is a 501(c)(3) not-for-profit medical professional society of influential research scientists, physician scientists, clinicians, patients, patient advocates, government representatives and industry leaders. Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word "cure" a reality for cancer patients everywhere.

EXPANSIVE REACH

SITC's community of scientists, practitioners and healthcare professionals spans the country.


Membership

- 47 U.S. states
- 56 comprehensive cancer centers represented

A Membership Driven Society

- 350 volunteers contributing across SITC
- 29 committees and taskforces
- 78 SITC champions at cancer care institutes

Membership Totals By Year



IMMUNOTHERAPY BY THE NUMBERS

Advancing the Science

Currently **100+** clinical trials ongoing in cancer immunotherapy

Potential for Cure
50% of metastatic Melanoma patients alive at 10 years*

Growth in the Field

147 approvals for immunotherapies in cancer since 2011

Increased Options
Immunotherapy indications for **33 different diseases**

*Dana Farber Cancer Institute - "Long-term Metastatic Melanoma Survival Dramatically Improves on Immunotherapy"